Treatment decisions for lymphoma are based on the type of pathology, stage, and functional status of the patient. Hodgkin’s lymphoma is mainly treated with a combination of chemotherapy combined with radiotherapy, and most early-stage Hodgkin’s lymphoma can be cured. Those who cannot achieve complete remission with the first treatment after standard chemotherapy regimens, also known as refractory Hodgkin lymphoma, have the worst prognosis and can be treated with chemotherapy without cross-resistant regimens combined with local radiotherapy, and those who are eligible can consider intense chemotherapy supported by autologous hematopoietic stem cell transplantation. The most important treatment for non-Hodgkin’s lymphoma is chemotherapy, especially for those with moderate to high malignancy, with some patients obtaining better results with targeted therapy. Radiation therapy also has a place in the treatment of non-Hodgkin’s lymphoma, while surgery is a useful option in the comprehensive treatment of certain lesions, such as the treatment of gastrointestinal lymphoma, especially when the tumor is at risk of local perforation. Lymphoblast lymphoma is highly malignant and has a high mortality rate, and needs to be treated according to modern treatment protocols for acute lymphoblastic leukemia, where cure is still possible. Although Burkitt’s lymphoma is highly malignant, it can still be cured in many patients with reasonable treatment.